Provigil study sparks debate over ability to enhance alertness

In a new study of Cephalon's Provigil, researchers concluded that night-shift workers taking the stimulant experienced significantly better alertness but nevertheless continued to report attention failures at the rate of once every two minutes. With more than 6 million Americans working late-night shifts, drug developers have been focused on improving alertness among workers who often complain of sleepiness. In an editorial in the New England Journal of Medicine, Robert C. Basner said it was impossible to determine what clinical benefits could be expected from the drug. Cephalon, however, focused on the positives.

"This study further clarifies the role excessive sleepiness plays in shift-work sleep disorder, and the value of Provigil in treating excessive sleepiness," said Paul Blake, Cephalon's executive vice president for medical and regulatory operations.

- read this report from the Philadelphia Inquirer for more

ALSO: Second-quarter losses have widened at Cephalon. Story

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.